- Home
- MIN vs ABSI Comparison
MIN vs ABSI Comparison
Compare MIN & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- ABSI
- Stock Information
- Founded
- MIN 1988
- ABSI 2011
- Country
- MIN United States
- ABSI United States
- Employees
- MIN N/A
- ABSI N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- ABSI Health Care
- Exchange
- MIN Nasdaq
- ABSI Nasdaq
- Market Cap
- MIN 306.1M
- ABSI 353.8M
- IPO Year
- MIN N/A
- ABSI 2021
- Fundamental
- Price
- MIN $2.69
- ABSI $2.80
- Analyst Decision
- MIN
- ABSI Strong Buy
- Analyst Count
- MIN 0
- ABSI 5
- Target Price
- MIN N/A
- ABSI $8.40
- AVG Volume (30 Days)
- MIN 331.0K
- ABSI 2.5M
- Earning Date
- MIN 01-01-0001
- ABSI 05-13-2025
- Dividend Yield
- MIN 7.31%
- ABSI N/A
- EPS Growth
- MIN N/A
- ABSI N/A
- EPS
- MIN 0.08
- ABSI N/A
- Revenue
- MIN N/A
- ABSI $4,534,000.00
- Revenue This Year
- MIN N/A
- ABSI $158.58
- Revenue Next Year
- MIN N/A
- ABSI $93.12
- P/E Ratio
- MIN $33.38
- ABSI N/A
- Revenue Growth
- MIN N/A
- ABSI N/A
- 52 Week Low
- MIN $2.52
- ABSI $2.01
- 52 Week High
- MIN $2.88
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- MIN 52.32
- ABSI 44.49
- Support Level
- MIN $2.65
- ABSI $2.85
- Resistance Level
- MIN $2.71
- ABSI $3.16
- Average True Range (ATR)
- MIN 0.03
- ABSI 0.20
- MACD
- MIN 0.00
- ABSI -0.03
- Stochastic Oscillator
- MIN 68.75
- ABSI 19.57
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.